omniture
logo
Search
天境生物科技（上海）有限公司 IMab
Media Room

Latest News

rss

I-Mab Announces Authorization of Stock Repurchase Program up to $20 Million

SHANGHAI and GAITHERSBURG, Md., July 15, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2020-07-16 04:15 21963

I-Mab and ABL Bio to Present Preclinical Data for Joint Bispecific Antibody Program at the 2020 American Association for Cancer Research Virtual Meeting II

SHANGHAI and GAITHERSBURG, Md., June 12, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2020-06-12 20:00 6938

I-Mab Announces Upcoming Participation at June Conferences

SHANGHAI and GAITHERSBURG, Md., May 29, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), ...

2020-05-29 20:00 5964

I-Mab Reports Interim Results from Part 1 Study for Anti-GM-CSF Antibody TJM2 to Treat COVID-19 Patients with Cytokine Release Syndrome

SHANGHAI and GAITHERSBURG, MD, May 27, 2020 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a clinical-stage...

2020-05-28 04:05 1665
I-Mab Reports Interim Results from Part 1 Study for Anti-GM-CSF Antibody TJM2 to Treat COVID-19 Patients with Cytokine Release Syndrome

I-Mab and Genexine Announce China NMPA Clearance for Phase 2 Clinical Trial of TJ107/HyLeukin-7™ in Glioblastoma Multiforme

SHANGHAI, GAITHERSBURG, Md. and SEOUL, South Korea, May 21, 2020 /PRNewswire/ -- I-Mab (NASDAQ: IMA...

2020-05-21 20:00 5692

I-Mab Expands Global Presence with New Hong Kong Office

SHANGHAI and ROCKVILLE, Md., May 20, 2020 /PRNewswire/ -- I-Mab (NASDAQ:IMAB), a clinical stage bio...

2020-05-20 16:00 7699

First Patient Dosed with I-Mab's CD73 Antibody TJD5 in Phase 1/2 Clinical Trial in China for Advanced Solid Tumors

SHANGHAI and ROCKVILLE, Md., May 13, 2020 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a clinical stage bi...

2020-05-13 20:00 5139

I-Mab Biopharma Announces Dosing of First Patient in a Pivotal Study of TJ202/MOR202 in Multiple Myeloma in Mainland China

SHANGHAI, Jan. 3, 2020 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a global biopharmaceutical compan...

2020-01-04 00:07 1808

I-Mab Biopharma Receives IND Approval from NMPA to Initiate Clinical Trials for its Anti-GM-CSF Monoclonal Antibody TJM2 in China

SHANGHAI, Nov. 14, 2019 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a China and U.S.-based clinical-...

2019-11-14 23:45 1045

I-Mab Biopharma Receives IND Approval in China for Proprietary CD73 Antibody TJD5

SHANGHAI, Oct. 4, 2019 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a China and U.S.-based clinical s...

2019-10-04 13:40 1323

I-Mab Biopharma Announces Clinical Collaboration to Evaluate TJC4 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Multiple Cancer Types

SHANGHAI, Sept. 23, 2019 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a China and U.S.-based clinical...

2019-09-23 19:00 1686

I-Mab Biopharma and TRACON Pharmaceuticals Announce Dosing of the First Patient in a Phase 1 Trial of the CD73 Antibody TJD5 in the U.S. in Patients with Advanced Solid Tumors

SHANGHAI and SAN DIEGO, Aug. 1, 2019 /PRNewswire/ -- I-Mab Biopharma (I-Mab), a China and U.S.-base...

2019-08-01 20:06 2306

MacroGenics and I-Mab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Enoblituzumab in Greater China

ROCKVILLE, Md. and SHANGHAI, July 10, 2019 /PRNewswire/ -- MacroGenics, Inc. (NASDAQ: MGNX), a clin...

2019-07-11 04:01 2383

I-Mab Announces Dosing of First Patient in a Phase I Clinical Trial of TJC4, a Potentially Differentiated CD47 Antibody, for the Treatment of Cancers in the United States

GAITHERSBURG, Md., June 25, 2019 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a clinical stage biotec...

2019-06-25 22:01 1904
1 ... 34567